Date: 2016-01-04
Type of information: Resignation
Compound:
Company: Erytech Pharma (France)
Therapeutic area: Cancer - Oncology
Type agreement: resignation
Action mechanism:
Disease:
Details: * On January 4, 2016, Erytech, a French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announced that Yann Godfrin will be leaving the company to pursue new entrepreneurial projects. Yann Godfrin is one of the co-founders of the company and the inventor of the ERYCAPS technology. Yann served as Chief Executive Office from the time of creation of the company in 2004 until 2010 and as Chief
Scientific Officer since then. The search for a replacement has been initiated. During the transition phase, Yann will continue to support the company on a consulting basis.
Financial terms:
Latest news:
